propranolol has been researched along with Hereditary Hemorrhagic Telangiectasia in 6 studies
Propranolol: A widely used non-cardioselective beta-adrenergic antagonist. Propranolol has been used for MYOCARDIAL INFARCTION; ARRHYTHMIA; ANGINA PECTORIS; HYPERTENSION; HYPERTHYROIDISM; MIGRAINE; PHEOCHROMOCYTOMA; and ANXIETY but adverse effects instigate replacement by newer drugs.
propranolol : A propanolamine that is propan-2-ol substituted by a propan-2-ylamino group at position 1 and a naphthalen-1-yloxy group at position 3.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The study demonstrated that combined therapy (sclerotherapy and topical nasal propranolol) significantly reduced the epistaxis due to HHT and increased patients' quality of life." | 7.91 | Sclerotherapy and Topical Nasal Propranolol: An Effective and Safe Therapy for HHT-Epistaxis. ( Botella Cubells, L; Esteban-Casado, S; Marcos Salazar, MS; Martín de Rosales Cabrera, AM; Martínez Simón, JJ; Pérez Encinas, M; Usarralde Pérez, A; Zhan Zhou, E, 2019) |
| "These preliminary results suggest that topical propranolol may be effective for the treatment of epistaxis in patients with HHT." | 7.85 | Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report. ( Blau, H; Bruckheimer, E; Goldschmidt, N; Mei-Zahav, M; Zur, E, 2017) |
| " Administration (systemically or topically via a spray or gel) of timolol and propranolol showed mixed evidence of improvement in epistaxis frequency, severity, and duration when compared with control groups." | 5.22 | The Use of Beta-Blockers in Hereditary Hemorrhagic Telangiectasia-Related Epistaxis: A Systematic Review. ( Albarki, H; Rimmer, J, 2022) |
| "The study demonstrated that combined therapy (sclerotherapy and topical nasal propranolol) significantly reduced the epistaxis due to HHT and increased patients' quality of life." | 3.91 | Sclerotherapy and Topical Nasal Propranolol: An Effective and Safe Therapy for HHT-Epistaxis. ( Botella Cubells, L; Esteban-Casado, S; Marcos Salazar, MS; Martín de Rosales Cabrera, AM; Martínez Simón, JJ; Pérez Encinas, M; Usarralde Pérez, A; Zhan Zhou, E, 2019) |
| "These preliminary results suggest that topical propranolol may be effective for the treatment of epistaxis in patients with HHT." | 3.85 | Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report. ( Blau, H; Bruckheimer, E; Goldschmidt, N; Mei-Zahav, M; Zur, E, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (83.33) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Albarki, H | 1 |
| Rimmer, J | 1 |
| Mei-Zahav, M | 1 |
| Blau, H | 1 |
| Bruckheimer, E | 1 |
| Zur, E | 1 |
| Goldschmidt, N | 1 |
| Esteban-Casado, S | 1 |
| Martín de Rosales Cabrera, AM | 1 |
| Usarralde Pérez, A | 1 |
| Martínez Simón, JJ | 1 |
| Zhan Zhou, E | 1 |
| Marcos Salazar, MS | 1 |
| Pérez Encinas, M | 1 |
| Botella Cubells, L | 1 |
| Contis, A | 1 |
| Gensous, N | 1 |
| Viallard, JF | 1 |
| Goizet, C | 1 |
| Léauté-Labrèze, C | 1 |
| Duffau, P | 1 |
| Albiñana, V | 1 |
| Recio-Poveda, L | 1 |
| Zarrabeitia, R | 1 |
| Bernabéu, C | 1 |
| Botella, LM | 1 |
| Breier, G | 1 |
1 review available for propranolol and Hereditary Hemorrhagic Telangiectasia
| Article | Year |
|---|---|
The Use of Beta-Blockers in Hereditary Hemorrhagic Telangiectasia-Related Epistaxis: A Systematic Review.
Topics: Epistaxis; Humans; Propranolol; Prospective Studies; Quality of Life; Randomized Controlled Trials a | 2022 |
5 other studies available for propranolol and Hereditary Hemorrhagic Telangiectasia
| Article | Year |
|---|---|
Topical propranolol improves epistaxis in patients with hereditary hemorrhagic telangiectasia - a preliminary report.
Topics: Administration, Intranasal; Administration, Topical; Adult; Aged; Dose-Response Relationship, Drug; | 2017 |
Sclerotherapy and Topical Nasal Propranolol: An Effective and Safe Therapy for HHT-Epistaxis.
Topics: Administration, Intranasal; Administration, Topical; Adult; Aged; Combined Modality Therapy; Cross-S | 2019 |
Efficacy and safety of propranolol for epistaxis in hereditary haemorrhagic telangiectasia: retrospective, then prospective study, in a total of 21 patients.
Topics: Adrenergic beta-Antagonists; Adult; Aged; Epistaxis; Female; Humans; Male; Middle Aged; Propranolol; | 2017 |
Propranolol as antiangiogenic candidate for the therapy of hereditary haemorrhagic telangiectasia.
Topics: Activin Receptors, Type II; Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Animals; Antigens, | 2012 |
Propanolol and angiogenesis inhibition in hereditary haemorrhagic telangiectasia.
Topics: Adrenergic beta-Antagonists; Angiogenesis Inhibitors; Animals; Endothelium, Vascular; Humans; Neovas | 2012 |